What is Bioxytran Financial Strength?
Bioxytran has the Financial Strength Rank of 4.
Warning Sign:
Bioxytran Inc displays poor financial strength. Usually, this is caused by too much debt for the company.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Bioxytran did not have earnings to cover the interest expense.
As of today, Bioxytran's Altman Z-Score is 0.00.
Competitive Comparison of Bioxytran's Financial Strength
For the Biotechnology subindustry, Bioxytran's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioxytran's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bioxytran's Financial Strength distribution charts can be found below:
* The bar in red indicates where Bioxytran's Financial Strength falls into.
Bioxytran Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Bioxytran's Interest Expense for the
months ended in Mar. 2024 was $-0.03 Mil. Its Operating Income for the
months ended in Mar. 2024 was $-0.79 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil.
Bioxytran's Interest Coverage for the quarter that ended in Mar. 2024 is
| Bioxytran did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Bioxytran's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Bioxytran has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioxytran (Bioxytran) Business Description
Traded in Other Exchanges
N/A
Address
75 2nd Avenue, Suite 605, Needham, MA, USA, 02494
Bioxytran Inc is a biopharmaceutical company. The company is engaged in developing anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia. It is also focusing on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. Its product candidate, BXT-25, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked. Its other drug candidate BXT-252 is a resuscitative agent in a variety of wound healing applications.
Executives
| Dale H Conaway |
director |
189 WELLS AVE, NEWTON MA 02459 |
| Alan M Hoberman |
director |
6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934 |
| Anders Utter |
director |
BIOXYTRAN, INC, 233 NEEDHAM ST., SUITE 300, NEWTON MA 02464 |
| David Platt |
director, 10 percent owner, officer: CEO |
12 APPLETON CIRCLE, NEWTON MA 02459 |
| Hana Chen-walden |
director |
7 RUE ARISTIDE MAILLOL, PARIS I0 75015 |
| Michael Sheikh |
officer: Chief Communication Officer |
1905 S AUDUBON CT, SPOKANE WA 99224 |
| Binder Offer |
other: No longer 10% owner |
PASQUALE VIA SETTEMBRIMI 14A, SAN MARIANO 06073, CORCIANO PG ITALY L6 00000 |
| Ola Soderquist |
10 percent owner, officer: CFO |
47 HAMMOND STREET, UNIT 2, WALTHAM MA 02451 |
| Lawrence W. Bonafide |
director |
78365 HWY 111, SUITE 287, LA QUINTA CA 92253 |
| Nathan Marks |
director |
78365 HWY 111, SUITE 287, LA QUINTA CA 92253 |
| Dave Quincy Farber |
director, officer: President |
78365 HWY 111, SUITE 287, LA QUINTA CA 92253 |
| David Lee |
director |
78365 HWY 111, SUITE 287, LA QUINTA CA 92253 |
| Donita R. Kendig |
director, officer: Secretary/Treasurer |
78365 HWY 11, SUITE 287, LA QUINTA CA 92253 |
| Afcc, Llc |
10 percent owner |
1621 CENTRAL AVENUE, CHEYENNE WY 82001 |
| Paul W Hai |
10 percent owner |
20443 TIMBERLINE, BEND OR 97701 |
Bioxytran (Bioxytran) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BIXT has been successfully added to your